Valuation: Alkermes plc

Market Cap 8.26B 7.15B 6.7B 6.11B 11.5B 787B 11.69B 78.53B 30.77B 394B 31B 30.32B 1,315B P/E 2026 *
-96.6x
P/E 2027 * 67.7x
Enterprise Value 9B 7.8B 7.3B 6.66B 12.54B 858B 12.75B 85.61B 33.54B 430B 33.79B 33.05B 1,433B EV / Sales 2026 *
4.93x
EV / Sales 2027 * 4.59x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day-0.38%
1 week-0.93%
Current month+0.45%
1 month-5.26%
3 months+38.74%
6 months+40.96%
Current year+75.88%
1 week 48.21
Extreme 48.21
50.4
1 month 47.66
Extreme 47.66
53.88
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
5/8/26 Free

Chief Executive Officer

217,534 0.1297%
3/8/26 Sell

Compliance Officer

-2,034 0.0012%
3/8/26 Fiscal year

Chief Technology Officer

19,000 0.0113%
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%-0.93%+85.42%+75.56% 8.26B
-0.83%+1.57%+4.43%+15.38% 49.54B
-0.69%+6.25%+492.36%+585.40% 44.06B
+0.08%+11.23%+23.99%+81.74% 40.85B
+0.76%+6.85%+35.40%+10.92% 40.14B
+4.73%+13.29%+27.76%+54.22% 34.17B
-0.41%+4.08% - - 16.78B
+0.51%+5.29%+34.62%+126.87% 16.9B
-0.26%+0.06%+4.40%+20.92% 14B
+1.81%+20.45%+89.35%+31.49% 13.46B
Average +0.53%+260.33%+88.64%+111.39% 27.82B
Weighted average by Cap. +0.52%+289.52%+106.42%+136.46%

Financials

2026 *2027 *
Net sales 1.82B 1.58B 1.48B 1.35B 2.54B 174B 2.58B 17.36B 6.8B 87.12B 6.85B 6.7B 291B 1.94B 1.69B 1.58B 1.44B 2.71B 185B 2.75B 18.5B 7.25B 92.83B 7.3B 7.14B 310B
Net income -89.92M -77.92M -72.95M -66.56M -125M -8.58B -127M -855M -335M -4.29B -338M -330M -14.32B 120M 104M 97.59M 89.04M 168M 11.47B 170M 1.14B 448M 5.74B 452M 442M 19.16B
Net Debt 744M 645M 604M 551M 1.04B 70.95B 1.05B 7.08B 2.77B 35.51B 2.79B 2.73B 118B 670M 581M 543M 496M 933M 63.9B 949M 6.37B 2.5B 31.98B 2.52B 2.46B 107B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
11/08/26 USD 49.21 -0.38% 1,373,601
10/08/26 USD 49.40 +0.47% 1,511,275
07/08/26 USD 49.17 +1.65% 1,110,968
06/08/26 USD 48.37 -2.50% 1,569,088
05/08/26 USD 49.61 -0.12% 1,706,769
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.21USD
Average target price
56.00USD
Spread / Average Target
+13.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock